Funded Biotechnology Startups in Norway
Across the 21 most recent biotech funding entries in Norway, one disclosed round stands well above the rest: Calluna Pharma’s $82M Series A on 2024-01-23.
Across the 21 most recent biotech funding entries in Norway, one disclosed round stands well above the rest: Calluna Pharma’s $82M Series A on 2024-01-23. Excluding undisclosed amounts, the next-highest disclosed figures are $76M (Actithera, 2025-07-09) and $55M (OptiNose, 2024-05-09), while most other disclosed rounds cluster between $2M and $15M.
The list also shows both a city concentration and a temporal cluster. Oslo appears repeatedly (e.g., Zelluna Immunotherapy on 2026-06-29 at $2M; Circio on 2026-06-10 at $32M; Calluna Pharma on 2024-01-23 at $82M), alongside other hubs like Trondheim (Biosergen AS at $4M on 2024-11-18; CardioMech at $13M on 2024-01-02) and Bergen (BerGenBio at $10M on 2022-10-25). Datewise, rounds are heavily weighted toward 2024–2026, spanning 2021-01-04 (Hemispherian, Pre-Seed) through 2026-06-29 (Zelluna Immunotherapy), with multiple entries in the first half of 2024 (e.g., OptiNose on 2024-05-09 at $55M; Calluna Pharma on 2024-01-23 at $82M).
Most recent rounds
21 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round here, and how does it compare to the rest of the disclosed amounts?
Calluna Pharma’s $82M Series A (2024-01-23) is the largest disclosed amount in the 21-row view. The next-largest disclosed rounds are Actithera’s $76M (2025-07-09) and OptiNose’s $55M (2024-05-09), while many other disclosed rounds sit much lower, including $2M–$15M entries like Zelluna Immunotherapy ($2M, 2026-06-29) and Hofseth BioCare ($15M, 2026-06-26).
Are there obvious time clusters among the most recent rounds shown?
Yes. The disclosed rounds concentrate strongly in 2024–2026, with multiple entries in early-to-mid 2024 such as Calluna Pharma ($82M, 2024-01-23), OptiNose ($55M, 2024-05-09), and Oncoinvent ($12M, 2024-12-04). The earliest row shown is Hemispherian’s Pre-Seed on 2021-01-04 ($100K), creating a long tail behind the more recent activity.
Does Oslo dominate, or are other cities competitive in this Norway biotech list?
Oslo is the most repeated location across the rows, including Zelluna Immunotherapy (2026-06-29, $2M), Circio (2026-06-10, $32M), and Calluna Pharma (2024-01-23, $82M). Other cities appear but less frequently, such as Trondheim with Biosergen AS (2024-11-18, $4M) and CardioMech (2024-01-02, $13M), and Bergen with BerGenBio (2022-10-25, $10M).
Which stage labels stand out relative to 'Series Unknown' in this dataset?
While most rows are labeled 'Series Unknown' (including Zelluna Immunotherapy on 2026-06-29 at $2M and Circio on 2026-06-10 at $32M), there are also explicit stages that cluster in the higher-amount range. Examples include Actithera’s Series A ($76M, 2025-07-09) and Calluna Pharma’s Series A ($82M, 2024-01-23), compared with smaller disclosed seed-style entries like NoMy (Seed, $1M, 2025-05-07) and NEC OncoImmunity AS (Seed, $5M, 2022-04-12).
Are there meaningful outliers on the low end that differ from the main funding band?
The smallest disclosed amounts are very low compared with the rest of the disclosed rounds: Nordic Nanovector’s $100K Post-IPO Equity (2022-03-14) and Hemispherian’s $100K Pre-Seed (2021-01-04). In contrast, the main disclosed amounts frequently fall in the single-digit millions through mid-teens, such as Biosergen AS at $4M (2024-11-18) and CardioMech at $13M (2024-01-02).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.